May 4, 2015

Studying Numb: a protein known to suppress breast cancer

Hello! My name is Ran Wei and I’m a PhD candidate in the Department of Biochemistry at Western University, working with Shawn Li, PhD.

Our lab is interested in discovering the pathways involved in the development of different cancers including breast cancer. Some changes in such pathways are intimately associated with cancer progression. One type of those tumour-related changes is post-translational modifications such as methylation. A post translational modification (PTM) is an addition to a protein after it has been made. We’re currently developing novel therapies by targeting these PTMs or their modifying enzymes.

One of my research interests is targeting Numb methylation. Numb is a protein known to suppress breast cancer, and the loss of Numb protein expression correlates positively with tumour aggressiveness and a poor prognosis.

Our previous study reveals that Numb methylation by the Set8 enzyme has a similar effect as loss-of-Numb. Therefore, it’s conceivable that inhibiting Numb methylation by a Set8 inhibitor has great therapeutic potential for the treatment of breast cancer.

Currently, there is no commercial inhibitor for Set8. We’ve used leading-edge technologies such as peptide microarrays and mass spectrometry to develop a potential Set8 peptide inhibitor called PR9-G8. PR9-G8 showed significant inhibition of Set8 activity. Currently, we’re testing the effects of PR9-G8 peptide in several different breast cancer cell lines and any effect will be further tested in mouse xenograft models.

I presented this work at Western’s 2013 Oncology Research & Education Day, where I won an award for my poster presentation.

Thank you to BCSC for your trainee support!
– Ran Wei, student researcher
Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, London Health Sciences Centre

Breast Cancer Canada: Canadian Night at ASCO 2026

Breast Cancer Canada warmly invites you to Canadian Night at ASCO 2026, a special evening to connect with Canadian researchers, patient advocates, and healthcare leaders

Survey: Cancer Care Navigation in Canada

Breast Cancer Canada has launched a national survey to better understand how cancer care navigation is experienced across the country, from both the patient and

Meet Anayra

Anayra Goncalves is a PhD student in the Department of Anatomy & Cell Biology at WesternUniversity. She is conducting BCC-funded breast cancer research under the

Understanding BRCA2

Breast cancer is the most commonly diagnosed cancer among women in Canada. While age remains the strongest risk factor, inherited genetic mutations also play an

Progress Through Research

Latest Research

Breast Cancer Canada donations fund life-saving research that directly impacts Canadian patients. That means better answers, bigger breakthroughs – and more personalized treatment for every breast cancer diagnosis.

Patient Tools

Our suite of digital tools are each designed to help individuals better manage their breast cancer journey through education, research and personalized insights, while also elevating the patient voice.

Patient Stories

Every breast cancer journey is unique, but together, these stories paint a powerful picture of progress. Through firsthand accounts from patients and survivors, we share stories that highlight the lived-experiences of breast cancer.

Fuel Progress

Progress happens when we invest in it. Canada is home to some of the world’s brightest minds in research. Together, we are advancing science, ensuring it leads to earlier detection, better treatments, and improved outcomes for patients across the country.